US Industry Gears Up For Biden Administration
AAM Chief Leonard Insists Generics Remain A ‘Bridge To A COVID-19 Vaccine’
US off-patent industry association the AAM has welcomed the prospect of working with the incoming Biden-Harris administration, emphasizing that there is “more to be done” to improve generic and biosimilar utilization and uptake.
You may also be interested in...
The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.
The AAM’s new CEO, Dan Leonard, has set out his priorities for the industry association, highlighting current industry challenges as well as throwing light on how generics can be the “bridge” to a COVID-19 vaccine.
Dan Leonard’s communications background, in addition to his policy expertise, may prove useful for the Association for Accessible Medicines as it navigates ongoing market and public policy challenges.